Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9818707rdf:typepubmed:Citationlld:pubmed
pubmed-article:9818707lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:9818707lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:9818707lifeskim:mentionsumls-concept:C0001563lld:lifeskim
pubmed-article:9818707lifeskim:mentionsumls-concept:C0076110lld:lifeskim
pubmed-article:9818707lifeskim:mentionsumls-concept:C0870883lld:lifeskim
pubmed-article:9818707lifeskim:mentionsumls-concept:C0205309lld:lifeskim
pubmed-article:9818707pubmed:issue7lld:pubmed
pubmed-article:9818707pubmed:dateCreated1999-1-29lld:pubmed
pubmed-article:9818707pubmed:abstractTextAs an extensive study, the pharmacokinetics of terbinafine and five known metabolites have been investigated after single and repeated oral administration to 12 pediatric patients. After single administration of 125 mg terbinafine, four compounds were unconjugated and the hydroxymetabolites appeared in trace amounts as glucuronides. The main metabolites in plasma were unconjugated carboxy compounds. Kinetics of terbinafine and N-desmethylterbinafine metabolite were comparable. The interindividual AUCt variability was similar for terbinafine, N-desmethylterbinafine and carboxyterbinafine. In urine, the major fraction was the hydrophilic unconjugated N-desmethyl-carboxyterbinafine (15%). After repeated administration of 125 mg day(-1), mean trough levels of terbinafine, N-desmethylterbinafine, carboxyterbinafine and N-desmethylhydroxy-terbinafine, and also that of hydroxyterbinafine metabolite were similar, for each compound, on days 21, 42 and 56 denoting that steady state was reached at least on day 21 and no accumulation occurred between days 21 and 56.lld:pubmed
pubmed-article:9818707pubmed:languageenglld:pubmed
pubmed-article:9818707pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9818707pubmed:citationSubsetIMlld:pubmed
pubmed-article:9818707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9818707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9818707pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9818707pubmed:statusMEDLINElld:pubmed
pubmed-article:9818707pubmed:monthOctlld:pubmed
pubmed-article:9818707pubmed:issn0142-2782lld:pubmed
pubmed-article:9818707pubmed:authorpubmed-author:SioufiAAlld:pubmed
pubmed-article:9818707pubmed:authorpubmed-author:HumbertHHlld:pubmed
pubmed-article:9818707pubmed:authorpubmed-author:CabiacM DMDlld:pubmed
pubmed-article:9818707pubmed:authorpubmed-author:LakhdarHHlld:pubmed
pubmed-article:9818707pubmed:authorpubmed-author:DenouëlJJlld:pubmed
pubmed-article:9818707pubmed:issnTypePrintlld:pubmed
pubmed-article:9818707pubmed:volume19lld:pubmed
pubmed-article:9818707pubmed:ownerNLMlld:pubmed
pubmed-article:9818707pubmed:authorsCompleteYlld:pubmed
pubmed-article:9818707pubmed:pagination417-23lld:pubmed
pubmed-article:9818707pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:9818707pubmed:meshHeadingpubmed-meshheading:9818707-...lld:pubmed
pubmed-article:9818707pubmed:meshHeadingpubmed-meshheading:9818707-...lld:pubmed
pubmed-article:9818707pubmed:meshHeadingpubmed-meshheading:9818707-...lld:pubmed
pubmed-article:9818707pubmed:meshHeadingpubmed-meshheading:9818707-...lld:pubmed
pubmed-article:9818707pubmed:meshHeadingpubmed-meshheading:9818707-...lld:pubmed
pubmed-article:9818707pubmed:meshHeadingpubmed-meshheading:9818707-...lld:pubmed
pubmed-article:9818707pubmed:meshHeadingpubmed-meshheading:9818707-...lld:pubmed
pubmed-article:9818707pubmed:meshHeadingpubmed-meshheading:9818707-...lld:pubmed
pubmed-article:9818707pubmed:meshHeadingpubmed-meshheading:9818707-...lld:pubmed
pubmed-article:9818707pubmed:meshHeadingpubmed-meshheading:9818707-...lld:pubmed
pubmed-article:9818707pubmed:year1998lld:pubmed
pubmed-article:9818707pubmed:articleTitlePharmacokinetics of terbinafine and five known metabolites in children, after oral administration.lld:pubmed
pubmed-article:9818707pubmed:affiliationDrug Metabolism and Pharmacokinetics, Novartis Pharma, Rueil-Malmaison, France.lld:pubmed
pubmed-article:9818707pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9818707pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9818707lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9818707lld:pubmed